Bionano Genomics, Inc. (BNGO)  announced today the launch of the largest study to date aiming to identify genomic variants and novel active substances that influence resistance or sensitivity to the SARS-CoV2 virus, or COVID-19, disease progression and drug response. The study will control for viral strain differences, and for the known risk factors of age and chronic illness such as heart disease, diabetes, or other immune-compromising disease. The first study of this kind is underway in Wuhan, China, and is being performed at the site of Wuhan-based GrandOmics, a service provider using Bionano technology.

Shares traded slightly lower following Q3 earnings of $0.47/share on sales of $27.974 billion. YETI (YETI) - Goldman Sachs upgraded the stock to Buy and set a new $37 price target. Goldman's new price target represented potential upside of 11%.

SAN DIEGO, Feb. 28, 2020 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.

Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, announced today that cancer, genetic disease and genomics researchers using the Saphyr system will present their results at the Advances in Genome Biology and Technology (AGBT) Conference taking place February 23 – 26 in Marco Island, Florida. The impact of Saphyr for genome-wide detection of structural variation will be highlighted at AGBT with a total of 19 oral and poster presentations and talks hosted by Bionano.

Bionano Genomics, Inc. (BNGO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bionano Genomics, Inc. (BNGO) announced that the University of Iowa Hospitals and Clinics (UIHC) will switch their method of clinical molecular testing for patients with presumed Facioscapulohumeral Muscular Dystrophy (FSHD) to optical mapping using Bionano’s Saphyr System. The UIHC recently completed development of an FSHD assay on Saphyr and validated its results by processing patient samples for FSHD.

Bionano Genomics, Inc. (BNGO) announced today that the following top European institutions have recently incorporated the Saphyr® system into their repertoire of solutions for genome analysis and are now operating them across a range of applications: Curie Institute in Paris, France; NHS Lothian in Edinburgh, Scotland; and MVZ Martinsried in Munich, Germany. The Saphyr system is designed to enable comprehensive analysis of genome structure, including genomic structural variations unresolved by current next-generation sequencing (NGS) technology.

Bionano Genomics (BNGO) today announced updates to the Saphyr® System designed to increase the speed of data collection, simplify sample preparation for solid tumors and animal tissue and significantly improve the total data yield per flow cell, allowing for a complete workflow for the in-depth analysis of complex, heterogeneous cancer samples. Bionano is also introducing two new ways for customers to access Bionano data:  the first, by offering a competitively priced service for human genome analysis, and the second, a reagent-rental model that provide scientists and labs with the Saphyr system when they make a certain minimum commitment to purchase Bionano consumables. As a result of the updates announced today, Saphyr can collect as much as 5 Terabasepairs of data, or over 1500x coverage of a human genome, in 48 to 96 hours on three samples in parallel, for a total of 15 Tbp on a single Saphyr Chip.

Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets the Saphyr® System, a genome imaging platform for ultra-sensitive and ultra-specific genome-wide structural variation detection, today announced the adoption of Saphyr by GeneDx, Inc., to develop assays that will transition to their clinical laboratory in Gaithersburg, MD. Assays based on the Bionano optical mapping technology will complement GeneDx’s current testing methodologies.

SAN DIEGO, March 05, 2020 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive.

Bionano Genomics, Inc. (BNGO) today announced that Erik Holmlin, Ph.D., CEO of Bionano, will participate on a panel entitled: “Testing and Susceptibility – Clearing the Air,” during the virtual conference “The Role of Cell Therapy & Clarity on Testing” hosted by Maxim Group and M-Vest today, Wednesday, May 27, 2020. The panel will include an interactive discussion moderated by Dr. Jason McCarthy, Biotechnology Analyst at Maxim. To access the panel discussion, please RSVP at https://m-vest.com/insights/blog/covid-19-virtual-conference.

Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that the company is relying on the order issued by the U.S. Securities and Exchange Commission to delay the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 due to circumstances related to the COVID-19 pandemic. The company plans to file the Form 10-Q and report its financial results for the quarter ended March 31, 2020 on June 18, 2020. In addition, due to uncertainties regarding the duration and impact of the COVID-19 pandemic, the company is suspending any guidance, anticipated timelines or other outlooks previously provided for 2020.

Bionano’s new DNA Isolation Kit for Bone Marrow Aspirates enables routine clinical analysis of Leukemia samples. SAN DIEGO, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets the Saphyr® System, a genome imaging platform for ultra-sensitive and ultra-specific genome-wide structural variation detection, today announced four leukemia studies using its technology published in the special edition of the prestigious journal Blood prior to the start of the Annual Meeting of the American Society of Hematology (ASH) being held December 7-10th in Orlando, Florida. Bionano is today also announcing the launch of its DNA isolation kit for Bone Marrow Aspirates (BMA), the primary material collected in leukemia patients.

SAN DIEGO, Jan. 10, 2020 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.

Bionano Genomics, Inc. (BNGO) announced today that a team led by Dr. Alexander Hoischen from Radboud University Medical Center (RUMC) in the Netherlands reported the results of a successful validation study comparing the performance of Bionano Genomics’ Saphyr® system to traditional cytogenetic methods for the clinical analysis of leukemia genomes. The study, published in bioRxiv, found that Saphyr was 100% concordant with the standard of care for the detection of somatic chromosomal abnormalities. In a diagnostic set-up, especially for hematological malignancies, the comprehensive analysis of all cytogenetic aberrations requires a combination of techniques, such as karyotyping, fluorescence in situ hybridization and CNV-microarrays.

Bionano Genomics announced the launch of a global network of studies aiming to identify genomic variants that influence COVID-19 disease resistance, sensitivity, disease progression and drug response. The first study will focus on the Wuhan, China outbreak, and will be performed at the site of Wuhan-based Bionano service provider GrandOmics in collaboration with Bionano Genomics. At least one hundred patients who tested positive for COVID-19 infection will undergo whole genome analysis using the Bionano Saphyr system, and genomic variants will be compared between those patients who show no or mild symptoms and those who show severe illness.

Bionano Genomics, Inc. (BNGO) today announced the appointment of Hannah Mamuszka and Yvonne Linney, PhD, to its board of directors. Junfeng Wang, who originally joined the company’s board as a representative of Legend Capital, a private equity firm that invested in the company before its initial public offering, has resigned as member of the board.

Bionano Genomics, Inc. (BNGO) announced today that Mayo Clinic has adopted the Saphyr system. A team led by Dr. Mark Ebbert brought the Saphyr system in-house after determining that Bionano’s technology can provide a deeper understanding of the genetic causes of neurodegenerative diseases and the routes to developing novel diagnostic assays and drugs to enable therapeutic interventions.

Bionano Genomics, Inc. (BNGO) announced that in an online presentation hosted by the Cancer Genomics Consortium (CGC) on May 12, 2020, Dr. Brynn Levy from Columbia University and Dr. Rashmi Kanagal-Shamanna from the MD Anderson Cancer Center each presented updates on their work showing 100% concordance between Bionano Genomics’ optical mapping technology and current gold standard cytogenetic methods. In his presentation, Dr. Levy reported on a blinded, prospective study comparing the results generated by Bionano’s Saphyr instrument to results from routine clinical testing in CLIA laboratories using current gold standard cytogenetic techniques.

BIONANO GENOMICS, INC. (BNGO), a genome analysis company that provides tools and services based on its Saphyr® system to scientists and clinicians conducting genetic research and patient testing, today announced the pricing of an underwritten public offering of 54,546,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and common warrants to purchase up to an aggregate of 54,546,000 shares of common stock. Each share of common stock and, as applicable, each pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.33 per share and accompanying common warrant.